Podcasts about humacyte

  • 24PODCASTS
  • 24EPISODES
  • 37mAVG DURATION
  • 1EPISODE EVERY OTHER WEEK
  • Dec 12, 2023LATEST

POPULARITY

20172018201920202021202220232024


Latest podcast episodes about humacyte

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 12, 2023 53:42


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy new jersey events patients md llc consultants addressing next generation pfizer advisor abbott astrazeneca medical education advanced study medtronic bristol myers squibb vox media penumbra unmet needs thrombosis anticoagulation radcliffe institute weitz frcpc planning committee biosensors accreditation council bayer ag improving care janssen pharmaceuticals pvi alnylam pharmaceuticals abiomed continuing medical education accme arena pharmaceuticals roxana mehran humacyte cardiovascular research foundation applied therapeutics medtelligence mjh life sciences novo nordisk inc practice aids peerview institute reviewer disclosuresplanners grant research support cme moc aapa disclosure policyall stock shareholder other financial daiichi sankyo inc pharmacy education acpe boston scientific corporation
PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 12, 2023 53:49


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy new jersey events patients md llc consultants addressing next generation pfizer advisor abbott astrazeneca medical education advanced study medtronic bristol myers squibb vox media penumbra unmet needs thrombosis anticoagulation radcliffe institute weitz frcpc planning committee biosensors accreditation council bayer ag improving care janssen pharmaceuticals pvi alnylam pharmaceuticals abiomed continuing medical education accme arena pharmaceuticals roxana mehran humacyte cardiovascular research foundation applied therapeutics medtelligence mjh life sciences novo nordisk inc practice aids peerview institute reviewer disclosuresplanners grant research support cme moc aapa disclosure policyall stock shareholder other financial daiichi sankyo inc pharmacy education acpe boston scientific corporation
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 12, 2023 53:49


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy new jersey events patients md llc consultants addressing next generation pfizer advisor abbott astrazeneca medical education advanced study medtronic bristol myers squibb vox media penumbra unmet needs thrombosis anticoagulation radcliffe institute weitz frcpc planning committee biosensors accreditation council bayer ag improving care janssen pharmaceuticals pvi alnylam pharmaceuticals abiomed continuing medical education accme arena pharmaceuticals roxana mehran humacyte cardiovascular research foundation applied therapeutics medtelligence mjh life sciences novo nordisk inc practice aids peerview institute reviewer disclosuresplanners grant research support cme moc aapa disclosure policyall stock shareholder other financial daiichi sankyo inc pharmacy education acpe boston scientific corporation
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 12, 2023 53:49


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy new jersey events patients md llc consultants addressing next generation pfizer advisor abbott astrazeneca medical education advanced study medtronic bristol myers squibb vox media penumbra unmet needs thrombosis anticoagulation radcliffe institute weitz frcpc planning committee biosensors accreditation council bayer ag improving care janssen pharmaceuticals pvi alnylam pharmaceuticals abiomed continuing medical education accme arena pharmaceuticals roxana mehran humacyte cardiovascular research foundation applied therapeutics medtelligence mjh life sciences novo nordisk inc practice aids peerview institute reviewer disclosuresplanners grant research support cme moc aapa disclosure policyall stock shareholder other financial daiichi sankyo inc pharmacy education acpe boston scientific corporation
PeerView Clinical Pharmacology CME/CNE/CPE Video
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Dec 12, 2023 53:42


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy new jersey events patients md llc consultants addressing next generation pfizer advisor abbott astrazeneca medical education advanced study medtronic bristol myers squibb vox media penumbra unmet needs thrombosis anticoagulation radcliffe institute weitz frcpc planning committee biosensors accreditation council bayer ag improving care janssen pharmaceuticals pvi alnylam pharmaceuticals abiomed continuing medical education accme arena pharmaceuticals roxana mehran humacyte cardiovascular research foundation applied therapeutics medtelligence mjh life sciences novo nordisk inc practice aids peerview institute reviewer disclosuresplanners grant research support cme moc aapa disclosure policyall stock shareholder other financial daiichi sankyo inc pharmacy education acpe boston scientific corporation
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 12, 2023 53:42


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy new jersey events patients md llc consultants addressing next generation pfizer advisor abbott astrazeneca medical education advanced study medtronic bristol myers squibb vox media penumbra unmet needs thrombosis anticoagulation radcliffe institute weitz frcpc planning committee biosensors accreditation council bayer ag improving care janssen pharmaceuticals pvi alnylam pharmaceuticals abiomed continuing medical education accme arena pharmaceuticals roxana mehran humacyte cardiovascular research foundation applied therapeutics medtelligence mjh life sciences novo nordisk inc practice aids peerview institute reviewer disclosuresplanners grant research support cme moc aapa disclosure policyall stock shareholder other financial daiichi sankyo inc pharmacy education acpe boston scientific corporation
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 12, 2023 53:42


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy new jersey events patients md llc consultants addressing next generation pfizer advisor abbott astrazeneca medical education advanced study medtronic bristol myers squibb vox media penumbra unmet needs thrombosis anticoagulation radcliffe institute weitz frcpc planning committee biosensors accreditation council bayer ag improving care janssen pharmaceuticals pvi alnylam pharmaceuticals abiomed continuing medical education accme arena pharmaceuticals roxana mehran humacyte cardiovascular research foundation applied therapeutics medtelligence mjh life sciences novo nordisk inc practice aids peerview institute reviewer disclosuresplanners grant research support cme moc aapa disclosure policyall stock shareholder other financial daiichi sankyo inc pharmacy education acpe boston scientific corporation
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Roxana Mehran, MD / Jeffrey Weitz, MD, FRCPC, FRSC, FACP - Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 12, 2023 53:49


This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPK865. CME/MOC/AAPA credit will be available until December 12, 2024.Addressing Unmet Needs in Anticoagulation for Thrombosis: Next-Generation Strategies for Improving Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from the Bristol Myers Squibb and Janssen Alliance.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerRoxana Mehran, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Abbott; ABIOMED; Affluent Medical; Alleviant Medical; Amgen Inc.; AM-Pharma B.V.; Arena Pharmaceuticals, Inc.; AstraZeneca; AtriCure Inc.; Biosensors; BIOTRONIK SE & Co KG; Boston Scientific Corporation; Bristol Myers Squibb; CardiaWave; Celonova Biosciences Inc.; Chiesi USA, Inc.; Concept Medical; Cytosorbents Europe GmbH; Daiichi Sankyo Inc.; Duke; Element Science, Inc.; Faraday Pharmaceuticals; Humacyte, Inc.; Idorsia Pharmaceuticals Ltd; Janssen Pharmaceuticals, Inc.; Koninklijke Philips N.V.; Magenta Therapeutics; M.A. Med Alliance SA; MediaSphere Medical LLC; Medtelligence; Medtronic; MJH Life Sciences; Novartis Pharmaceuticals Corporation; OrbusNeich Medical Company Group Holdings Limited; Penumbra, Inc.; PhaseBio Pharmaceuticals, Inc.; Pi-Cardia; PLx Pharma Inc.; Protembis GmbH; RenalPro; RM Global Partners; Shockwave Medical Inc.; Vivasure Medical Limited; and ZOLL Medical Corporation.Honoraria from ACC (BOT Member, SC Member CTR Program) and JAMA Cardiology (Associate Editor).Stock Shareholder in Applied Therapeutics and Elixir Therapeutics, LLC.Other Financial or Material Support in the form of personal fees from Affluent Medical; Cardiovascular Research Foundation; Daiichi Sankyo Brasil; ER Squibb & Sons LLC; Esperion Therapeutics, Inc.; Europa Group/Boston Scientific Corporation; Gaffney Events Educational Trust; Ionis Pharmaceuticals; IQVIA Inc; J-CalC; McVeigh Global Meetings and Events; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Oversome; Primer Healthcare of New Jersey; Radcliffe Institute for Advanced Study; SL Solutions LLC; TARSUS Cardiology; Vectura Group Ltd; and Vox Media, LLC.Co-Chair/PlannerJeffrey Weitz, MD, FRCPC, FRSC, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alnylam Pharmaceuticals, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Honoraria from Ionis Pharmaceuticals; Janssen Inc.; Merck & Co., Inc.; Pfizer; and Servier Canada.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

strategy new jersey events patients md llc consultants addressing next generation pfizer advisor abbott astrazeneca medical education advanced study medtronic bristol myers squibb vox media penumbra unmet needs thrombosis anticoagulation radcliffe institute weitz frcpc planning committee biosensors accreditation council bayer ag improving care janssen pharmaceuticals pvi alnylam pharmaceuticals abiomed continuing medical education accme arena pharmaceuticals roxana mehran humacyte cardiovascular research foundation applied therapeutics medtelligence mjh life sciences novo nordisk inc practice aids peerview institute reviewer disclosuresplanners grant research support cme moc aapa disclosure policyall stock shareholder other financial daiichi sankyo inc pharmacy education acpe boston scientific corporation
LifeSci Partners Podcast
Regenerative Medicine from Humacyte: Off-the-Shelf, Human-Sourced Acellular Vessels for Traumatic Wound Repair

LifeSci Partners Podcast

Play Episode Listen Later Feb 10, 2023 36:04


In the clinical setting, the time it takes to address a serious problem can make the difference between life and death. To save as much time as possible, the necessary material – a vessel to do a coronary bypass, for example – needs to be readily available. However, due to the organic nature of that material, acquisition may take more time than you have, and the nature of the end-product may be suboptimal. Enter Humacyte. Using human-sourced cells, Humacyte creates Human Acellular Vessels (HAVs) that are non-immunogenic and available on demand. HAVs are in Phase 3 testing in the settings of both arteriovenous (AV) access, as needed for kidney dialysis, and trauma, as seen in severe injury, such as a war wounds. This indication has attracted the attention of the US Department of Defense and the Ukrainian army – where compassionate use is already underway. And, this is just the beginning. Listen in as Humacyte's CEO Dr. Laura E. Niklason tells the Humacyte story.

ESC TV Today – Your Cardiovascular News
Episode 9: Among the topics: Cardiac involvement in Fabry's disease - Anti-thrombotic therapy post PCI: DAPT in 2023

ESC TV Today – Your Cardiovascular News

Play Episode Listen Later Feb 9, 2023 19:41


ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Cardiac involvement in Fabry's Disease Anti-thrombotic therapy post PCI: DAPT in 2023  Mythbusters: Powernap for heart health Host: Rick Grobbee Guests: Perry Elliott, Nicolle Kraenkel, Roxana Mehran and Franz Weidinger Want to watch that episode? Go to: https://esc365.escardio.org/event/896 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes.  The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.  Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.  Declarations of interests  Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Franz Weidinger have declared to have no potential conflicts of interest to report.  Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede.  Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Daiichi Sankyo, Terumo, Medtronic, Chiesi.  Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Sanofi. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Abiomed, Alleviant Medical, Amgen, AM-Pharma, Arena, AstraZeneca, Atricure, Bayer, Biosensors, Biotronik, Boston Scientific, Bristol-Myers Squibb, CardiaWave, CeloNova, Chiesi, Concept Medical, CSL Behring, Cytosorbents, Daiichi Sankyo, Element Science, Faraday, Filterlex Medical, Humacyte, Idorsia Pharmaceuticals, Janssen, Mediasphere, Medtelligence, Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll;  personal fees from Cine-Med Research, Ionis Pharmaceuticals, Novartis, Novo Nordisk, Vectura, WebMD; Equity

Beyond Biotech - the podcast from Labiotech
Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene

Beyond Biotech - the podcast from Labiotech

Play Episode Listen Later Dec 9, 2022 62:11


2:33 Labiotech.eu news5:03 Humacyte23:01 Transgene37:21 Center for Global Development54:32 JLLThis week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance.We also have our weekly commentary from Travis McCready at JLL.HumacyteThe ongoing war in Ukraine continues to present significant challenges for frontline hospitals in treating the injured. As part of the humanitarian aid effort, U.S. biotech, Humacyte, has worked with the FDA and the Ukrainian Ministry of Health to send 30 investigational bioengineered blood vessels to help repair tissue injuries from bomb and gunshot wounds. Humacyte's human acellular vessels, or HAVs, are off-the-shelf replacement vessels that help the body heal itself. They are currently being evaluated in multiple advanced-stage clinical trials in vascular trauma  repair, arteriovenous access for hemodialysis and peripheral arterial disease and so far, have been implanted in more than 500 patients to date.   The HAV is made by seeding vascular cells from a qualified cell bank onto a biocompatible, biodegradable polymer mesh in a bioreactor bag. Over weeks, the cells grow and create new tissue, forming a tube-shaped vessel structure while the polymer mesh degrades. The resulting bioengineered vessel is then decellularized to create the HAV: an extracellular matrix that retains the biomechanical properties of the vessel but is cleansed of cellular components that could induce an immune response. The HAV in the bioreactor bag can then be shipped, stored, and is immediately available when needed.  Reaction to European Union action on antimicrobial resistanceFourteen Member States wrote to the European Commission recently outlining why they think the EU's proposed policies around antimicrobial resistance (AMR) are costly, inefficient, and will disrupt the market for generic drugs.Anthony McDonnell, senior policy analyst at the Center for Global Development, looked in detail at the EU's proposals, why member states are revolting against it, and which policies the EU should actually implement to successfully combat AMR.He said that, for months it has been speculated that the EU may move toward transferable exclusivity vouchers (TEVs). The14 countries have made three counter proposals for how new antimicrobials can be encouraged. TransgeneTransgene is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Its programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.The company's clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO platform).With Transgene's myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. myvac  allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by AI capabilities provided by its partner NEC.With its proprietary platform Invir.IO, Transgene is designing a new generation of multifunctional oncolytic viruses. It has an ongoing collaboration with AstraZeneca.Subscribe to our newsletter

The BME Grad Podcast
16- MSAT Engineering at Humacyte + Job Searching on a Student Visa w/ Luciana Herrero

The BME Grad Podcast

Play Episode Listen Later Nov 25, 2022 34:03


Lucy Herrero discusses Humacyte, her role as a Manufacturing Science and Technology (MSAT) Engineer at Humacyte, and provides advice on searching for jobs with a student visa. Lucy Herrero's Bio: After earning my bachelor's degree in Biomedical Engineering at University of North Carolina at Chapel Hill, I entered the regenerative medicine world to fulfill my purpose of helping others through my career. I strive to serve with excellence as I collaborate in the optimization and operation of the LUNA200 platform at Humacyte. In addition to my primary job functions, I was recently recognized for leading and implementing a novel sitewide alarm management procedure, as well as developing program in Matlab for the quality control of raw materials. One of my favorite achievements is publishing an article at the Human Movement Science Journal as a primary author in 2020. Currently, my goal is to build expertise in tech transfer and knowledge management. Outside of work you can find me hiking with my dog or reading fantasy novels. More on The BME Grad Podcast: www.thebmegradpodcast.com Subscribe on YouTube: www.youtube.com/channel/UCyfF0xH80d5lS1RpQsmpw0Q/videos Follow us on LinkedIn: www.linkedin.com/company/thebmegradpodcast/ Follow us on Instagram: www.instagram.com/thebmegradpodcast/ --- Support this podcast: https://anchor.fm/the-bme-grad/support

The BME Grad Podcast
16- MSAT Engineering at Humacyte + Job Searching on a Student Visa w/ Luciana Herrero

The BME Grad Podcast

Play Episode Listen Later Nov 25, 2022 34:03


Lucy Herrero discusses Humacyte, her role as a Manufacturing Science and Technology (MSAT) Engineer at Humacyte, and provides advice on searching for jobs with a student visa. Lucy Herrero's Bio: After earning my bachelor's degree in Biomedical Engineering at University of North Carolina at Chapel Hill, I entered the regenerative medicine world to fulfill my purpose of helping others through my career. I strive to serve with excellence as I collaborate in the optimization and operation of the LUNA200 platform at Humacyte. In addition to my primary job functions, I was recently recognized for leading and implementing a novel sitewide alarm management procedure, as well as developing program in Matlab for the quality control of raw materials. One of my favorite achievements is publishing an article at the Human Movement Science Journal as a primary author in 2020. Currently, my goal is to build expertise in tech transfer and knowledge management. Outside of work you can find me hiking with my dog or reading fantasy novels. More on The BME Grad Podcast: www.thebmegradpodcast.com Subscribe on YouTube: www.youtube.com/channel/UCyfF0xH80d5lS1RpQsmpw0Q/videos Follow us on LinkedIn: www.linkedin.com/company/thebmegradpodcast/ Follow us on Instagram: www.instagram.com/thebmegradpodcast/ --- Support this podcast: https://anchor.fm/the-bme-grad/support

LATAM Medtech Leaders
Mauricio Berdugo, Director of Medical Affairs at Humacyte

LATAM Medtech Leaders

Play Episode Listen Later Nov 17, 2022 29:58 Transcription Available


Mauricio A. Berdugo, MD, MPH, is currently the Director of Medical Affairs at Humacyte, Inc. Mauricio has worked in different capacities within the CRO, pharma, diagnostics, and biotech industries in the USA and globally, including Latin America, Europe, and Asia over the past 9 years.  His clinical and academic research stems from HIV/AIDS, cardiovascular disease, pulmonary disease, renal disease, and orthopedic spine surgery. Mauricio graduated from medical school at the Universidad Evangelica de El Salvador, completed his Master of Public Health degree from Kaplan University, and he is currently pursuing a Fellowship with the American College of Healthcare Executives.

Global Medical Office Dialogues
Humacyte and its humanitarian aid to Ukraine with Laura Niklason, MD, PhD

Global Medical Office Dialogues

Play Episode Listen Later Nov 16, 2022 12:59


Human Acellular Vessels are bioengineered blood conduits which have shown great promise in clinical trials for vascular applications, including arteriovenous access for hemodialysis, peripheral arterial disease, and trauma repair. Dr. Laura Niklason, Founder and CEO of Humacyte, discusses this promising technology and its recent deployment as humanitarian aid for repairing vascular trauma in Ukraine.

The Bio Report
A Regenerative Medicine Company Puts Its Off-the-Shelf Vessel Replacements to the Test in Ukraine

The Bio Report

Play Episode Listen Later Jun 9, 2022 25:07


Humacyte's human acellular vessels are experimental, engineered, off-the-shelf replacement vessels that are being developed for vascular repair, reconstruction, and replacement. The vessels are designed to overcome long-standing limitations in vessel tissue repair and replacement. Though not yet approved, the manufactured vessels are getting a real-world test as the company has been providing them to hospitals in Ukraine to treat wounded civilians and soldiers with vascular injuries. We spoke to Laura Niklason, CEO of Humacyte, about the company's human acellular vessels, how they are produced, and the potential needs they can address.

Medtech Matters
Humacyte's Bioengineered Tissue Platform Technology

Medtech Matters

Play Episode Listen Later Mar 8, 2022 32:14


In this episode of Medtech Matters, a podcast focused on the medical device manufacturing industry and the factors impacting it, we speak with Dr. Juliana Blum, Co-founder and Executive Vice President of Corporate Development at Humacyte. She speaks to the technology behind their regenerative solution and how it can be leveraged as a technology platform to fulfill a variety of bioengineered tissue needs. Specifically, the following questions are addressed.What is Humacyte and tell us a bit about your technology?What are the applications for bioengineered tissue?Obviously without giving away trade secrets, can you tell us a bit about how it is fabricated?What were the major challenges that needed to be overcome to develop this?What's ahead for Humacyte?Listen to this episode and see what you think of the company's bioengineered tissue technology platform. If you'd like to share thoughts, ask questions, or suggest a future participant for Medtech Matters, please reach out to me at sfenske@rodmanmedia.com.

Biotech 2050 Podcast
89. Regenerative medicine pioneer, Laura Niklason, Founder, President, & CEO, Humacyte, Inc.

Biotech 2050 Podcast

Play Episode Listen Later Feb 9, 2022 33:38


A physician-scientist, her groundbreaking work in vascular and lung engineering has made Dr. Niklason a world leader in regenerative medicine. She is a member of the National Academies of Engineering and Medicine. Dr. Niklason is the founder of Humacyte and has served as President and Chief Executive Officer since November 2020 and as a member of the Humacyte Board since 2004. Dr. Niklason holds a Ph.D. in Biophysics from the University of Chicago and an M.D. from the University of Michigan.

Business Of Biotech
Bioenginnering Human Tissue With Humacyte's Dr. Heather Prichard

Business Of Biotech

Play Episode Listen Later Jan 3, 2022 41:01


Humacyte COO Dr. Heather Prichard joins the Business of Biotech for a discussion on the company's pipeline of candidates for the repair, replacement, and reconstruction of human vascular vessels. The company recently scaled the production of its implantable bioengineered human tissues from 10 to 200 per day to meet Phase 3 vascular trauma and arteriovenous access trials. On today's episode, Dr. Prichard shares the company's scale-up story and the science and engineering behind a unique approach to regenerative medicine using human tissue. 

Life Science Today
Life Science Today 066 – Cassava, Reify, Humacyte, Pfizer + Moderna + FDA, Ascendis

Life Science Today

Play Episode Listen Later Aug 30, 2021 9:21 Transcription Available


Originally Published as The Niche PodcastThe Cassava saga, Reify goes big… too big? Humacyte SPAC, vax news you already know, and a new growth hormone therapy – approved! Find out more athttps://thenichepod.comStory Referenceshttps://tinyurl.com/Niche-066-1https://tinyurl.com/Niche-066-2https://tinyurl.com/Niche-066-3https://tinyurl.com/Niche-066-4https://tinyurl.com/Niche-066-5https://tinyurl.com/Niche-066-6https://tinyurl.com/Niche-066-7Music by Luke Goodsonhttps://www.soundcloud.com/lukegoodsonLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

SPAC #Edge
SPAC #Edge: The Journey from Science Fiction to Science Fact: A Scientific Sponsor Meets a SPAC Sponsor

SPAC #Edge

Play Episode Listen Later Jul 2, 2021 59:56


In this episode of SPAC #Edge, Mark Yusko speaks to a SPAC sponsor and the CEO of a company that went public via a SPAC. Laura Niklason, MD., PhD., founder and CEO of Humacyte, a clinical-stage biotechnology platform company, and Rajiv Shukla, CEO of Alpha Healthcare Acquisition Corp, provide their unique perspective of the SPAC process from each side of the SPAC structure. Humacyte, a first-in-class business and the ideal type of business for a SPAC, recently completed a merger with Alpha HealthCare's SPAC.   You'll hear about their experience around the SPAC merger process and how science fiction, in their experience, truly became science fact.   To learn more about SPACs, Morgan Creek, and the investment solutions we offer, visit us on the web at https://www.morgancreekcap.com or contact us at IR@morgancreekcap.com.

McGowan Institute for Regenerative Medicine
RMT Podcast #222 – Juliana Blum

McGowan Institute for Regenerative Medicine

Play Episode Listen Later Jun 25, 2021 22:06


Regenerative Medicine Today welcomes Dr. Juliana Blum  Dr. Blum is the Co-Founder and Executive Vice President Corporate Development of Humacyte, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at a commercial scale. Dr. Blum discusses her work at Humacyte, focusing on the development and manufacture of bioengineered human tissues. This podcast was recorded in conjunction with the Journal [...]

Tested Podcast
A Durham Biotech Is Growing Replacement Human Arteries

Tested Podcast

Play Episode Listen Later May 17, 2021 11:26


A company with roots in a Duke University lab is developing implantable human tissue right here in Research Triangle Park. Humacyte is led by co-founder and chief executive Dr. Laura Niklason, who says this is a first-of-its kind breakthrough that could save thousands of limbs from amputation, improve care for patients on hemodialysis, and more. Host Jason deBruyn explains the potential health breakthrough and talks with Niklason about the company's history and future.

Field Notes
Bioengineered Blood Vessels: Exploring Potential Improvements in Dialysis Access for Patients with Dr. Laura Nikalson of Humacyte

Field Notes

Play Episode Listen Later Sep 15, 2020 17:00


Dr. Laura Niklason, co-founder of Humacyte, joins Field Notes to discuss the exciting potential of her company's human acellular vessel, which could transform vascular access for dialysis patients

patients improvements dialysis field notes blood vessels bioengineered humacyte laura niklason